These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068 [TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials. Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322 [TBL] [Abstract][Full Text] [Related]
9. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Vaduganathan M; Claggett BL; Lam CSP; Pitt B; Senni M; Shah SJ; Voors AA; Zannad F; Desai AS; Jhund PS; Viswanathan P; Bomfim Wirtz A; Schloemer P; Lay-Flurrie J; McMurray JJV; Solomon SD Eur J Heart Fail; 2024 Jun; 26(6):1324-1333. PubMed ID: 38742248 [TBL] [Abstract][Full Text] [Related]
10. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy. Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B; J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. Cox ZL; Collins SP; Aaron M; Hernandez GA; Iii ATM; Davidson BT; Fowler M; Lindsell CJ; Jr FEH; Jenkins CA; Kampe C; Miller KF; Stubblefield WB; Lindenfeld J Am Heart J; 2021 Feb; 232():116-124. PubMed ID: 33144086 [TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ; Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974 [TBL] [Abstract][Full Text] [Related]
17. Race influences the safety and efficacy of spironolactone in severe heart failure. Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD; Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307 [TBL] [Abstract][Full Text] [Related]
18. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF. Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796 [TBL] [Abstract][Full Text] [Related]
19. Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure. Kobayashi M; Yamashina A; Satomi K; Tezuka A; Ito S; Asakura M; Kitakaze M; Ferreira JP Int J Cardiol; 2024 Nov; 415():132477. PubMed ID: 39181408 [TBL] [Abstract][Full Text] [Related]
20. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Kociol RD; McNulty SE; Hernandez AF; Lee KL; Redfield MM; Tracy RP; Braunwald E; O'Connor CM; Felker GM; Circ Heart Fail; 2013 Mar; 6(2):240-5. PubMed ID: 23250981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]